242PD Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792).
Authors
Telli, MLord, S
Dean, Emma J
Abramson, V
Arkenau, H-T
Becerra, C
Tolaney, S
Tang, R
Penney, M
Pollard, J
Conboy, G
Fields, S
Shapiro, G
Affiliation
Oncology, Stanford University School of Medicine, StanfordIssue Date
2017-09
Metadata
Show full item recordCitation
242PD Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792). 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx365.005Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.005/4108471/242PDInitial-results-of-a-phase-1-dose-expansionType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx365.005